NRC
REGN icon

New Republic Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

New Republic Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-290
Closed -$224K – 365
2025
Q4 		$224K Buy
+290
New +$197K 0.06% 272

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

New Republic Capital's REGN Position: Q1 2026 in Review

New Republic Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 290 shares — an estimated $224K sold.

New Republic Capital first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $224K in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • New Republic Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • New Republic Capital sold 290 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $224K.
  • New Republic Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • New Republic Capital's Regeneron Pharmaceuticals position peaked at $224K in Q4 2025.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on New Republic Capital's 13F filing for Q1 2026, filed 1 May 2026.